Key Stats for TMO Stock
- Past-Week Performance: 10%
- 52-Week Range: $385 to $644
- Valuation Model Target Price: around $650
- Implied Upside: 33%
Analyze your favorite stocks like Thermo Fisher Scientific with TIKR (It’s free) >>>
What Happened?
Thermo Fisher Scientific Inc. stock rose about 10% this week, recently trading near $490 per share as investors rotated back into one of the largest life sciences tools, diagnostics, and biopharma services companies in the market. The move followed earlier weakness in the stock, with investors comparing Thermo Fisher against life sciences peers such as Danaher, Agilent Technologies, Waters, Bio-Rad Laboratories, and Revvity as the market looks for signs that lab spending, biotech funding, and pharma services demand are starting to recover.
The stock moved higher this week because investors got a clearer 2026 recovery story from better-than-expected Q1 results, Thermo Fisher’s Investor Day, and analyst targets that still leave room for upside despite recent cuts. Thermo Fisher reported Q1 revenue of $11.01 billion, up 6% year over year, and adjusted EPS of $5.44, while its 2026 adjusted EPS guidance remained at $24.64 to $25.12. Recent analyst updates stayed constructive overall, with Wells Fargo around $615, Stifel around $600, and BofA around $630, suggesting Wall Street still sees upside if customer spending improves.
At Investor Day this week, Thermo Fisher framed its 2026 setup around improving end markets, stronger biotech activity, AI-driven demand, and disciplined capital deployment, with CEO Marc Casper saying the company is “uniquely positioned to win.” Management pointed to 3% to 4% organic revenue growth, 8% to 10% adjusted EPS growth, 70 basis points of adjusted operating margin expansion, and $6.9 billion to $7.4 billion of free cash flow for 2026, while highlighting Clario, Solventum’s filtration business, U.S. pharma manufacturing reshoring, and stronger biopharma demand as key drivers this year.
Recent filings also showed a mixed ownership picture, with some large investors trimming positions while others added to or opened stakes. National Pension Service trimmed its stake by 0.6%, Huntington National Bank cut its position by 12%, and GS Investments reduced its stake by 24%, but Retail Employees Superannuation Trust opened a new position worth about $10 million, Fideuram Asset Management Ireland bought about $7 million of shares, Employees Retirement System of Texas raised its stake by 27%, Geode Capital added about 26,000 shares, and Baker Avenue increased its position by 9%. That mix matters because Thermo Fisher remains widely held by large investors even after expectations reset, giving the weekly rebound more support than a simple one-day bounce.
Value Thermo Fisher Scientific instantly (Free with TIKR) >>>
Is TMO Undervalued?
Under valuation assumptions, the stock is modeled using:
- Revenue Growth (CAGR): 6%
- Operating Margins: 24%
- Exit P/E Multiple: 19x
Thermo Fisher’s valuation case depends on whether the company can turn improving biopharma demand, biotech funding, and clinical research activity into steadier organic growth this year.
The business could perform better if Clario strengthens Thermo Fisher’s clinical research offering, Solventum’s filtration assets lift bioproduction growth, and U.S. pharma manufacturing investments create more demand for CDMO capacity, lab equipment, and bioprocessing tools.
See analysts’ growth forecasts and price targets for Thermo Fisher Scientific (It’s free) >>>
That matters because bioproduction supports biologic drug manufacturing, CDMO services help drugmakers outsource development and production, and Clario adds clinical-trial endpoint data that can make Thermo Fisher more valuable to pharma and biotech customers running complex studies.
Margin recovery also remains important because Thermo Fisher is guiding for 70 basis points of adjusted operating margin expansion in 2026, which suggests earnings can grow faster than sales if productivity, pricing, and acquisition synergies come through.
Based on these inputs, the model estimates a target price of around $650, implying about 33% total upside over roughly 3 years, suggesting Thermo Fisher appears undervalued at current prices.
At current levels, Thermo Fisher looks undervalued, with the next stage of the stock’s performance likely driven by customer spending recovery, new product adoption, clinical research growth, and management’s ability to turn improving order trends into stronger organic growth.
How Much Upside Does TMO Stock Have From Here?
Investors can estimate Thermo Fisher Scientific’s potential share price, or what any stock could be worth, in under a minute using TIKR’s New Valuation Model tool.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
Value Thermo Fisher Scientific in under 60 seconds with TIKR (It’s free) >>>
